COLLPLANT BIOTECHNOLOGIES LTD (NASDAQ: CLGN)

1. Introduction

CollPlant Biotechnologies Ltd. (“CollPlant”) is a biotechnology company focused on developing products for regenerative medicine and medical aesthetics. Headquartered in Rehovot, Israel, CollPlant utilizes a proprietary plant-based platform to produce recombinant human collagen (rhCollagen) that is used in 3D bioprinting of tissues and organs as well as in dermal and soft tissue fillers.

• Ticker: CLGN
• Exchange: NASDAQ (NAS)
• Share Price (2025-05-28): $2.5974 (+34.58%)
• Trading Volume: 535,967 shares

2. Corporate Structure

• Founded: 2004
• Employees: 51–200 (LinkedIn); 11–50 (AnnualReports)
• Key Executives:
  • Yehiel Tal, Chief Executive Officer
  • Eran Rotem, Deputy CEO & CFO
• Headquarters:
  CollPlant Biotechnologies Ltd.
  4 Oppenheimer St., P.O.B. 4132
  Rehovot 7670104, Israel

3. Recent Developments and News

• April 15, 2025 – U.S. Patent Granted
  CollPlant received U.S. Patent No. 12,186,449 for its photocurable dermal filler candidate. This event triggered a $2 million contingent payment under the 2021 agreement with AbbVie.
• Cost Reduction Plan (May 2025)
  A workforce reduction of approximately 20% was announced, expected to extend operational runway to at least Q2 2026. Remaining resources will support primary research and development programs, including the regenerative breast implant project.
• SEC Filing – Form 6-K (May 28, 2025)
  This filing provides information regarding the first-quarter results for 2025 and a corporate update (detailed metrics available in Exhibit 99.1).
• AbbVie Partnership
  AbbVie is managing clinical trials for CollPlant’s dermal and soft tissue filler under a worldwide exclusive license, with trial milestones guiding development payments.

4. Financial and Strategic Analysis

Metric	Value	Source / Date
Market Cap	$29.75 million (intraday)	Yahoo Finance (5/28)
52-Week Range	$1.55 – $5.895	Yahoo Finance
Beta (5-Year Monthly)	0.65	Yahoo Finance
Price/Sales (TTM)	42.93	Yahoo Finance
Price/Book (MRQ)	1.64	Yahoo Finance
Trailing Net Loss (TTM)	–$16.61 million	Yahoo Finance
Revenue (TTM)	$0.515 million	Yahoo Finance
Cash & Equivalents (MRQ)	$11.91 million	Yahoo Finance
Total Debt/Equity (MRQ)	22.88%	Yahoo Finance

• R&D Focus: CollPlant is investing in its rhCollagen platform for 3D-printed breast implants and medical aesthetic products.
• Cash Runway: Following cost-cutting measures, operational liquidity is projected to last through Q2 2026, reducing reliance on near-term financing.
• Strategic Payments: The $2 million milestone from AbbVie and future royalties from the collaboration are expected to support cash inflows.

5. Market Position and Industry Context

• Sector: Healthcare / Biotechnology
• Specialty: Regenerative medicine, 3D bioprinting, medical aesthetics
• Competitive Landscape: The company competes with firms like 3D Systems, BICO Group, and Merck in the bioink and bioprinting technology sectors.
• Market Growth: The global 3D bioprinting market is projected to expand from $1.3 billion in 2024 to $2.4 billion by 2029.
• Regulatory Alignment: CollPlant’s technologies are positioned to align with FDA initiatives aimed at reducing animal testing, with rhCollagen BioInks serving as a non-animal preclinical testing platform.
• ESG Commitment: CollPlant has been an active participant in the UN Global Compact since September 7, 2023, with the first Communication on Progress anticipated by July 31, 2025.

---

TL;DR

• On April 15, 2025, CollPlant secured U.S. Patent No. 12,186,449 for its photocurable dermal filler, resulting in a $2 million payment from AbbVie.
• A 20% workforce reduction in May 2025 aims to extend the company’s cash runway into Q2 2026.
• Stock price at $2.5974 (+34.58%) signals increased market interest; trailing loss is recorded at $16.61 million with $11.91 million in cash reserves.
• The partnership with AbbVie is ongoing, with clinical trials for dermal and soft tissue fillers and outcome milestones expected to drive future financial inflows.